---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-114430"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:12:01.239607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks

## Summary
- Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.
- R&D expense down to $11.8M from $19.5M; G&A down to $11.9M from $14.9M.
- Cash $58.8M at Mar 31, plus $25M Nestlé installment expected July 2025; runway into Q1 2026.
- Plans SER-155 Phase 2 study (248 patients, adaptive design) with interim analysis within 12 months of start.
- Regained Nasdaq compliance after 1-for-20 reverse stock split on April 21, 2025.

## SEC filing metadata
- accession: 0001193125-25-114430
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/0001193125-25-114430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-114430
- JSON: https://secwatch.observer/filing/0001193125-25-114430.json
- Plain text: https://secwatch.observer/filing/0001193125-25-114430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.